Richard P. Mattick is the Professor of Drug and Alcohol Studies in the National Drug & Alcohol Research Centre at the University of New South Wales, Sydney within the Faculty of Medicine. He has authored over 100 scientific articles and books on the assessment, nature and treatment of emotional, cognitive and psychological and neuropsychological problems. His major current research interests are in clinical trials for management of opioid dependence, psychostimulant substitution therapy, treatment of young drug dependent people, and the effects on cognitive functioning of exposure to psychostimulants and opioids.
He was the coordinator of the federally funded National Evaluation of Pharmacotherapies for Opioid Dependence studying 1500 opioid dependent patients assessing the impact of naltrexone, methadone, buprenorphine, and LAAM. He has conducted the largest randomised clinical trial of buprenorphine versus methadone, and this study is a pivotal study for the US FDA registration of buprenorphine. He is an Editor on the Cochrane Review Group for Drugs and Alcohol, and Assistant Editor and Executive Editor (respectively) on the international journals Addiction and the Drug and Alcohol Review.